Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 139
- 试验地点
- 22
- 主要终点
- Collect clinical and biological information in patients with CDG-PMM2
研究概览
简要总结
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)
This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).
详细描述
Subjects enrolled in this natural history study will be thoroughly examined for signs and symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging studies will be performed during a single consultation. Follow-up will occur every 3- 6 months at a minimum, depending on the standard of care at the investigator's institution as well as the clinical status of the individual patient. All medical procedures are routine. No new therapy is offered as part of this study, and no change in the patients routine therapy is dictated by this protocol. The International Co-Operative Ataxia Rating Scale (ICARS) is to be performed every 3 months as an optional assessment. No randomization will be performed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent/assent by the patient and/or their legally authorized representative
- •Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests
- •Willing and able to adhere to study requirements described in the protocol and consent/assent documents
排除标准
- •Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG)
- •Currently using investigational drug
- •Blood loss of ≥ 250 mL or donated blood within 56 days, or donated plasma within 7 days before study screening
结局指标
主要结局
Collect clinical and biological information in patients with CDG-PMM2
时间窗: up to 5 years
Growth parameter, organ function tests, developmental tests, standard laboratory tests, disease severity score according to Nijmegen Paediatric CDG Rating Scale (NPCRS)
次要结局
未报告次要终点
